TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Fortunato Morabito; Giovanni Del Poeta; Francesca Romana Mauro; Gianluigi Reda; Paolo Sportoletti; Luca Laurenti; Marta Coscia; Yair Herishanu; Sabrina Bossio; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Andrea Visentin; Adalgisa Condoluci; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Anna Grazia Recchia; Francesca Maria Rossi; Antonella Zucchetto; Hamdi Al-Janazreh; Enrica Antonia Martino; Ernesto Vigna; Giovanni Tripepi; Graziella D'Arrigo; Sara Galimberti; Angela Rago; Ilaria Angeletti; Annalisa Biagi; Ilaria Del Giudice; Riccardo Bomben; Antonino Neri; Gilberto Fronza; Giovanna Cutrona; Ozren Jaksic; Jacopo Olivieri; Davide Rossi; Francesco Di Raimondo; Antonio Cuneo; Gianluca Gaidano; Aaron Polliack; Livio Trentin; Robin Foà; Manlio Ferrarini; Valter Gattei; Massimo Gentile

doi:10.1002/ajh.26235

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Anna Grazia RecchiaFrancesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jaksic, Jacopo Olivieri, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Lingua originale	Inglese
pagine (da-a)	E306-E310
Rivista	American Journal of Hematology
Volume	96
Numero di pubblicazione	8
DOI	https://doi.org/10.1002/ajh.26235
Stato di pubblicazione	Pubblicato - 1 ago 2021

Accesso al documento

10.1002/ajh.26235

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Morabito, F., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., ... Gentile, M. (2021). TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 96(8), E306-E310. https://doi.org/10.1002/ajh.26235

@article{21e31f403adb49d7ad24ee5e94da52f6,

title = "TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases",

author = "Fortunato Morabito and \{Del Poeta\}, Giovanni and Mauro, \{Francesca Romana\} and Gianluigi Reda and Paolo Sportoletti and Luca Laurenti and Marta Coscia and Yair Herishanu and Sabrina Bossio and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Andrea Visentin and Adalgisa Condoluci and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Recchia, \{Anna Grazia\} and Rossi, \{Francesca Maria\} and Antonella Zucchetto and Hamdi Al-Janazreh and Martino, \{Enrica Antonia\} and Ernesto Vigna and Giovanni Tripepi and Graziella D'Arrigo and Sara Galimberti and Angela Rago and Ilaria Angeletti and Annalisa Biagi and \{Del Giudice\}, Ilaria and Riccardo Bomben and Antonino Neri and Gilberto Fronza and Giovanna Cutrona and Ozren Jaksic and Jacopo Olivieri and Davide Rossi and \{Di Raimondo\}, Francesco and Antonio Cuneo and Gianluca Gaidano and Aaron Polliack and Livio Trentin and Robin Fo{\`a} and Manlio Ferrarini and Valter Gattei and Massimo Gentile",

note = "Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.) and n. 21198, (to R.F); AIRC and Fondazione CaRiCal co‐financed Multi‐Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687 (to V.G.) IG‐5506 (to G.F.); Ricerca Finalizzata PE 2016‐02362756, Ministero della Salute, Rome, Italy (to V.G.); Progetto Ricerca Finalizzata RF‐2018‐12365790, Ministero della Salute, Rome, Italy (to A.Z. and G.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy (to R.F. and G.G.); Swiss Cancer League, ID 3746, 4395 4660, and 4705, Bern, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE, ID: 772051; Swiss National Science Foundation, ID 320030\_169670/1 and 310030\_192439, Berne, Switzerland; The Leukemia \& Lymphoma Society, Translational Research Program, ID 6594‐20, New York. Funding of the project was also provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR‐17‐10250). Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.) and n. 21198, (to R.F); AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.) IG-5506 (to G.F.); Ricerca Finalizzata PE 2016-02362756, Ministero della Salute, Rome, Italy (to V.G.); Progetto Ricerca Finalizzata RF-2018-12365790, Ministero della Salute, Rome, Italy (to A.Z. and G.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy (to R.F. and G.G.); Swiss Cancer League, ID 3746, 4395 4660, and 4705, Bern, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE, ID: 772051; Swiss National Science Foundation, ID 320030\_169670/1 and 310030\_192439, Berne, Switzerland; The Leukemia \& Lymphoma Society, Translational Research Program, ID 6594-20, New York. Funding of the project was also provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR-17-10250).",

year = "2021",

month = aug,

day = "1",

doi = "10.1002/ajh.26235",

language = "English",

volume = "96",

pages = "E306--E310",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

Morabito, F, Del Poeta, G, Mauro, FR, Reda, G, Sportoletti, P, Laurenti, L, Coscia, M, Herishanu, Y, Bossio, S, Varettoni, M, Murru, R, Chiarenza, A, Visentin, A, Condoluci, A, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Recchia, AG, Rossi, FM, Zucchetto, A, Al-Janazreh, H, Martino, EA, Vigna, E, Tripepi, G, D'Arrigo, G, Galimberti, S, Rago, A, Angeletti, I, Biagi, A, Del Giudice, I, Bomben, R, Neri, A, Fronza, G, Cutrona, G, Jaksic, O, Olivieri, J, Rossi, D, Di Raimondo, F, Cuneo, A, Gaidano, G, Polliack, A, Trentin, L, Foà, R, Ferrarini, M, Gattei, V & Gentile, M 2021, 'TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases', American Journal of Hematology, vol. 96, n. 8, pagg. E306-E310. https://doi.org/10.1002/ajh.26235

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. / Morabito, Fortunato; Del Poeta, Giovanni; Mauro, Francesca Romana et al.
In: American Journal of Hematology, Vol. 96, N. 8, 01.08.2021, pag. E306-E310.

Risultato della ricerca: Contributo su rivista › Lettera › peer review

TY - JOUR

T1 - TP53 disruption as a risk factor in the era of targeted therapies

T2 - A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

AU - Morabito, Fortunato

AU - Del Poeta, Giovanni

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Sportoletti, Paolo

AU - Laurenti, Luca

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Bossio, Sabrina

AU - Varettoni, Marzia

AU - Murru, Roberta

AU - Chiarenza, Annalisa

AU - Visentin, Andrea

AU - Condoluci, Adalgisa

AU - Moia, Riccardo

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Consoli, Ugo

AU - Scortechini, Ilaria

AU - Recchia, Anna Grazia

AU - Rossi, Francesca Maria

AU - Zucchetto, Antonella

AU - Al-Janazreh, Hamdi

AU - Martino, Enrica Antonia

AU - Vigna, Ernesto

AU - Tripepi, Giovanni

AU - D'Arrigo, Graziella

AU - Galimberti, Sara

AU - Rago, Angela

AU - Angeletti, Ilaria

AU - Biagi, Annalisa

AU - Del Giudice, Ilaria

AU - Bomben, Riccardo

AU - Neri, Antonino

AU - Fronza, Gilberto

AU - Cutrona, Giovanna

AU - Jaksic, Ozren

AU - Olivieri, Jacopo

AU - Rossi, Davide

AU - Di Raimondo, Francesco

AU - Cuneo, Antonio

AU - Gaidano, Gianluca

AU - Polliack, Aaron

AU - Trentin, Livio

AU - Foà, Robin

AU - Ferrarini, Manlio

AU - Gattei, Valter

AU - Gentile, Massimo

N1 - Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.) and n. 21198, (to R.F); AIRC and Fondazione CaRiCal co‐financed Multi‐Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687 (to V.G.) IG‐5506 (to G.F.); Ricerca Finalizzata PE 2016‐02362756, Ministero della Salute, Rome, Italy (to V.G.); Progetto Ricerca Finalizzata RF‐2018‐12365790, Ministero della Salute, Rome, Italy (to A.Z. and G.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy (to R.F. and G.G.); Swiss Cancer League, ID 3746, 4395 4660, and 4705, Bern, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE, ID: 772051; Swiss National Science Foundation, ID 320030_169670/1 and 310030_192439, Berne, Switzerland; The Leukemia & Lymphoma Society, Translational Research Program, ID 6594‐20, New York. Funding of the project was also provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR‐17‐10250). Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 × mille n.9980, (to F.M.) and n. 21198, (to R.F); AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 n.16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.) IG-5506 (to G.F.); Ricerca Finalizzata PE 2016-02362756, Ministero della Salute, Rome, Italy (to V.G.); Progetto Ricerca Finalizzata RF-2018-12365790, Ministero della Salute, Rome, Italy (to A.Z. and G.G.); Compagnia S. Paolo, Turin, Italy (Project 2017.0526 to G.F.) and by the Ministry of Health (Project 5 × 1000, 2015 and 2016 and Current Research 2016 to G.F.). AIRC 5 × 1000 No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy (to R.F. and G.G.); Swiss Cancer League, ID 3746, 4395 4660, and 4705, Bern, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE, ID: 772051; Swiss National Science Foundation, ID 320030_169670/1 and 310030_192439, Berne, Switzerland; The Leukemia & Lymphoma Society, Translational Research Program, ID 6594-20, New York. Funding of the project was also provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication (ISR-17-10250).

PY - 2021/8/1

Y1 - 2021/8/1

UR - https://www.scopus.com/pages/publications/85106298365

U2 - 10.1002/ajh.26235

DO - 10.1002/ajh.26235

M3 - Letter

SN - 0361-8609

VL - 96

SP - E306-E310

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 8

ER -